OCX Oncocyte

iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation

iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation

NASHVILLE, Tenn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced members of its management team will participate in the following investor conferences this winter, which will include hosting meetings around the annual J.P. Morgan Healthcare Conference.

LifeSci Advisors 15th Annual Corporate Access Event

Date: Monday, January 12th

Location: The Beacon Grand, San Francisco, Calif.

Format: One-on-one meetings with management

Additional “JPM Week” Investor Meetings

Date: Monday, January 12th through Wednesday, January 14th

Location: San Francisco, Calif.

Format: One-on-one meetings with management

BTIG 13th Annual Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Date: February 9th11th

Location: Cliff Lodge, Snowbird, Utah

Format: One-on-one meetings and skiing with management



To request an in-person meeting with management on Monday, January 12th, during the week of the 44th Annual J.P. Morgan Healthcare Conference, either register at  or contact our LifeSci Partners representatives Alexandra Grossman (). For meetings at the BTIG conference, please contact your sales representative at BTIG.

About Insight Molecular Diagnostics, Inc.

Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit  for more information.

Investor Contact:

Doug Farrell

LifeSci Advisors LLC



EN
07/01/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oncocyte

 PRESS RELEASE

IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25Welcomed second favorable head-to-head data set from an independent study at large hospital comparing GraftAssure to a leading centralized transplant rejection testExpect U.K. CE marking via self-certification in Q2 2026Completed $26 million financing in February; funds intended to support expansion into heart transplantation market while also commercializing testing for kidney NASHVILLE, Tenn., March 26, 2026 (GLOBE N...

 PRESS RELEASE

iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Atte...

iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market closes on Thursday, March 26, 2026. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: ...

 PRESS RELEASE

Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprieta...

Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score New data supports GraftAssure commercialization effortsMulti-center study featured 249 biopsy-matched patientsProprietary “Combination Model” score outperformed percentage-only measures of dd-cfDNAReinforces data presented at World Transplant Congress in 2025 NASHVILLE, Tenn., March 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today highlighted the of a new peer-reviewed study demonstrating the potential superiority of the company’s fla...

 PRESS RELEASE

Insight Molecular Diagnostics Completes Key Milestones Advancing Graft...

Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission Three-site reproducibility study completed by Tampa General Hospital, Mayo Clinic, and Baylor Scott & White HealthSufficient clinical samples collected to support statistical analysis and FDA submissionCompany achieved final ISO 13485 certification on Feb. 26, enabling U.K. and E.U. regulatory submissions NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today announced that in February the company completed several major miles...

 PRESS RELEASE

iMDx Announces $26.0 Million Registered Direct Offering

iMDx Announces $26.0 Million Registered Direct Offering NASHVILLE, Tenn., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (“iMDx” or the “Company”), today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of an aggregate of 4,525,976 shares of its common stock, no par value per share (or pre-funded warrants in lieu thereof) at an offering price of $5.75 per share in a registered direct offering. The purchase price per pre-funded warrant is identical to the purchase price per share o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch